Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Cert. of designation
Quarterly results
Appointed COO
Appointed director
Perspective Therapeutics, Inc. (ISR) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/29/2021 GN Isoray To Announce Third Quarter Fiscal 2021 Financial Results on May 13, 2021
03/31/2021 GN University Hospitals Cleveland Medical Center Pilot Study Shows Promise for High-Risk Recurrent Head and Neck Cancer Treatment with Cesium-131 and Surgical Resection
03/03/2021 GN Isoray to Present at the Oppenheimer 31st Annual Healthcare Conference
02/16/2021 GN Isoray Announces the Appointment of Lisa Lauer As Vice President Business Development
02/09/2021 GN Isoray Announces Second Quarter Fiscal 2021 Financial Results
02/05/2021 GN Isoray To Announce Second Quarter Fiscal 2021 Financial Results on February 9, 2021
02/04/2021 GN Isoray Announces Pricing of $45 Million Public Offering
02/03/2021 GN Isoray Announces Proposed Underwritten Public Offering
01/07/2021 GN Isoray to Present at the H.C. Wainwright BioConnect 2021 Conference
01/05/2021 GN C4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray's Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer
11/24/2020 GN Isoray's Cesium-131 Spotlighted in Multiple Presentations at ASTRO
11/02/2020 GN Isoray To Announce First Quarter Fiscal 2021 Financial Results on November 10, 2020
10/19/2020 GN Isoray, Inc. Announces Proposed Underwritten Public Offering
09/17/2020 GN Isoray Announces Fourth Quarter and Full-Year Fiscal Year End 2020 Financial Results
06/17/2020 GN Isoray and University of Cincinnati Physicians Company Sign Research Agreement to Study Treatment of Head and Neck Cancers 

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy